These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 462569)

  • 1. Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
    Greco C; Corsi A; Caputo M; Cavallari A; Calabresi F
    Tumori; 1979 Apr; 65(2):169-80. PubMed ID: 462569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.
    Corsi A; Calabresi F; Greco C
    Br J Cancer; 1978 Nov; 38(5):631-3. PubMed ID: 728352
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
    Kuśnierczyk H; Radzikowski C; Paprocka M; Budzyński W; Rak J; Kinas R; Misiura K; Stec W
    J Immunopharmacol; 1986; 8(4):455-80. PubMed ID: 3805744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
    Klein HO; Wickramanayake PD; Christian E; Coerper C
    Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide in experimental tumor systems.
    Goldin A
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):14-23. PubMed ID: 6761864
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
    Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide--pharmacology, safety and therapeutic potential.
    Brade WP; Herdrich K; Varini M
    Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
    [No Abstract]   [Full Text] [Related]  

  • 8. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
    Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
    Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
    Glazman-Kuśnierczyk H; Matuszyk J; Radzikowski C
    Immunopharmacol Immunotoxicol; 1992; 14(4):883-911. PubMed ID: 1294626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
    Klein HO; Wickramanayake PD; Christian E; Coerper C
    Cancer; 1984 Sep; 54(6 Suppl):1193-203. PubMed ID: 6432305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
    Brock N; Pohl J; Stekar J; Scheef W
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P; van Putten LM
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of combining the radiosensitizer misonidazole with cyclophosphamide in treating the murine Lewis lung tumor.
    Pedersen JE; Barron G; Meeker BE
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):651-3. PubMed ID: 7107392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
    Stoychkov JN; Miloushev AS
    Biomedicine; 1980 Apr; 33(2):42-4. PubMed ID: 6447522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of Iphosphamide in phracological treatment of neoplasms].
    Madej G; Zelechowska JA
    Pol Tyg Lek; 1975 Jun; 30(22):955-7. PubMed ID: 1135071
    [No Abstract]   [Full Text] [Related]  

  • 16. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
    Atassi G; Hilgard P; Pohl J
    Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide chemotherapy of intrapulmonarily implanted Lewis lung carcinoma.
    Ho W; Furst A
    Proc West Pharmacol Soc; 1978; 21():397-400. PubMed ID: 693524
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical toxicology of ifosfamide.
    Barnett D
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):8-13. PubMed ID: 6761867
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
    Phelan ET; Vietti TJ; Valeriote FA; Coulter D
    Anticancer Res; 1981; 1(3):149-54. PubMed ID: 7342853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.